Hospitals face chronic shortages of injectable opioids. The COVID-19 pandemic made things worse.

Vizient, a group purchasing organization that negotiates lower prices with drug manufacturers, sent recommendations that the Food and Drug Administration expand access to drugs heavily used with ventilator patients.
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

For years, hospitals chased supplies, sometimes resorting to inferior substitutes. The shortfall grew so dire in 2018 that a drugmaker sent letters advising hospitals they could use batches of opioid syringes potentially containing hazardous contaminants – so long as they filtered each dose.

[Editor’s note: Opioid pills and patches have been heavily used during the ongoing US overdose epidemic. Hospitals have been dealing with shortages of these painkillers in an injectable form. Now the COVID-19 pandemic has increased demand.]

Then the novel coronavirus struck, and demand for injectable opioids exploded. By April, more than 16,000 COVID-19 patients a day were on ventilators.

Underlying the persistent shortages – and the present crisis – are the basic economics of the American drug industry. The market discourages production of low-margin hospital injectable opioids in favor of high-profit prescription versions.

Related article:  What the porn industry can teach us about how to live safely with coronavirus

Though deficiencies in the supply of injectable opioids had long been recognized, U.S. drug makers, hospitals, regulators and lawmakers failed to fix the problem and were caught unprepared for a pandemic that suddenly and dramatically escalated demand, Reuters found.

Sen. Susan Collins, a Republican from Maine, said she had pushed for new incentives to encourage manufacturing of drugs at risk of shortage earlier this year, but federal agencies told her they did not want to pursue substantive action amid the pandemic. “This is a really important issue, and the coronavirus has really shined a light on it,” Collins told Reuters.

Read the original post

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend